Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y258
UPID:
CCL26_HUMAN
Alternative names:
CC chemokine IMAC; Eotaxin-3; Macrophage inflammatory protein 4-alpha; Small-inducible cytokine A26; Thymic stroma chemokine-1
Alternative UPACC:
Q9Y258; A0N0Q5; Q52LV8
Background:
C-C motif chemokine 26, also known as Eotaxin-3, plays a pivotal role in immune responses, acting as a chemoattractant for eosinophils and basophils. It binds to C-C chemokine receptor CCR3, triggering Ca(2+) mobilization in eosinophils, and serves as a ligand for CX3C chemokine receptor CX3CR1, inducing cell chemotaxis.
Therapeutic significance:
Understanding the role of C-C motif chemokine 26 could open doors to potential therapeutic strategies.